Investors weren’t impressed with Puma Biotechnology (PBYI) latest earnings report, and at least one Wall Street analyst has had enough. J.
Cowen’s Chris Shibutani is out downgrading and cutting his price target on PUMA stock, now seeing a mere 2% in upside potential.
A European approval seems unlikely.
Puma Biotechnology Inc (NASDAQ:PBYI) has won FDA approval for its lead candidate Nerlynx (neratinib), sending shares up 9% in Tuesday’s trading session. The drug …
J.P.
In a 12-4 vote, the FDA’s Oncologic Drugs Advisory Committee (ODAC) supported the approval of Puma Biotechnology Inc’s (NASDAQ:PBYI) breast cancer drug neratinib, sending the drug maker’s shares …
It is a good day to be a Puma Biotechnology Inc (NASDAQ:PBYI) investors, with shares soaring 38% and FDA sentiment looking favorably on …
It’s a very rewarding trading day for investors in Puma Biotechnology Inc (NASDAQ:PBYI) with shares up over 40%, making the stock Wall Street’s …
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares skyrocketed over 65% this morning, after the drug maker announced top-line results from its AURA-LV Phase IIb study …
Today, while many news outlets attributed Puma Biotechnology Inc’s (NYSE:PBYI) collapse to the news that the biotech company is under investigation for allegedly failing to inform …
